Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Clinical Applications: The range of clinical applications for albumin considerably affects the market. Albumin, a fundamental plasma protein, is liable for the guideline of circulatory strain and volume. It is broadly utilized in clinical mediations, for example, in basic consideration for patients going through consumes, as a plasma volume expander, and in circumstances requiring liquid revival. The creation and appropriation of albumins are impacted by market drifts that start from its interest in clinical settings.
Expanding geriatric Populace: A significant component impacting the market is the worldwide geriatric populace. The probability of creating ailments that might require albumin supplementation increments with age. The need for albumin-based medical interventions rises in response to age-related increases in the incidence of critical illnesses and conditions like nephrosis and liver cirrhosis.
Surgeries and Liver Illnesses: The need for albumin is significantly increased by liver diseases and surgical procedures. Cirrhosis of the liver is habitually joined by hypoalbuminemia, a condition set apart by strangely low albumin levels in the blood. This inadequacy is habitually treated with albumin implantations, particularly preceding and following liver tasks; this influences the market elements.
The albumin market is fundamentally affected by the overall blood plasma supply. Albumin is gotten from human plasma; Consequently, the albumin supply as a whole is affected by changes in plasma collection regulations or accessibility. Albumin creation and availability are straightforwardly impacted by the smoothness of the blood plasma area, incorporating assortment procedures and administrative benchmarks.
Persistent endeavours in innovative work assume a huge part in the progression of items and treatments in view of albumin. Drug organizations apportion assets towards the examination of novel albumin applications, including details and medication conveyance frameworks. Market development is affected by mechanical headways in albumins and the extent of clinical applications is expanded.
The worldwide predominance of cardiovascular infections, which are critical supporters of dismalness and mortality, impacts the requirement for albumins. In cardiogenic shock and heart failure, fluid imbalances are frequently treated with albumin. The need for albumin based clinical intercessions is straightforwardly related with the commonness of cardiovascular illnesses.
Worldwide Wellbeing Emergency Reaction: Worldwide wellbeing emergencies, including the continuous Coronavirus pandemic, can possibly affect the market. In the midst of general wellbeing emergencies, basic consideration conditions might observer a flood in the requirement for albumin, which is regulated to control confusions like intense respiratory misery disorder. Medical care needs and pandemic reactions impact the creation and circulation of albumins.
The administrative climate fundamentally impacts the turn of events and construction of the market. The assortment, handling, and appropriation of blood plasma are dependent upon severe guidelines, which defend the trustworthiness and security of albumin items. Administrative standard changes or the conceding of endorsements for novel applications can possibly apply an effect on market elements and the cutthroat climate.
Arising Economies and Medical services Framework: The state of healthcare infrastructure in emerging economies has an impact on the growth of the albumin market. The progression of medical services frameworks in non-industrial countries adds to the uplifted accessibility of albumin-based treatments. Expanding consciousness of clinical mediations and financial development are the essential elements driving albumin request in these districts.
Mechanical Progressions in Albumin Creation: Market viability and cost-adequacy are impacted by mechanical advances in albumin creation. Associations designate assets towards improving creation processes, like recombinant advances, determined to expand the versatility and financial reasonability of albumin. The effect of mechanical progressions on estimating methodologies and market intensity is significant.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Size Value In 2022 | USD 0.9 Billion |
| Market Size Value In 2023 | USD 0.95 Billion |
| Growth Rate | Â 5.9% (2023-2032) |
Albumin Market Highlights:
Global Albumin Market Overview
The Albumin (as Excipient) Market Size was valued at USD 0.9 billion in 2022 and is projected to grow from USD 0.95 Billion in 2023 to USD 1.46 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.9% during the forecast period (2023 - 2032). Rising research and development activities and increased government investment are just a few market drivers.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Albumin Market Trends
- Increased demand for certified Albumin (as Excipient) products to propel market growth
Human Albumin is frequently used as a plasma expander or replacement for therapeutic purposes. The use of human Albumin as a non-therapeutic substance or excipient for commercial settings has, however, been under investigation by the healthcare sector for more than ten years. Emerging markets for human Albumin as a component of vaccines, a surgical sealant, and a coating for medical equipment and devices are anticipated to drive production across all of these application areas. The demand for Albumin in laboratories is rising as people become more aware of its advantages. It functions as a pharmaceutical stabilizer to lessen the denaturation of the proteins' active components. Additionally, human serum albumin has a number of advantages that make it a good option for vaccine formulations. It is anticipated that advances in molecular separation and protein purification technology will significantly boost the market. Thus, this aspect is expected to accelerate Albumin (as an excipient) market revenue globally.
There are several benefits of using Albumin during drug formation. Pharmaceutical drug development faces a challenge in creating safe and stable formulations, and selecting excipients can play a significant role in the formulation's success. This is especially important for difficult-to-formulate active pharmaceutical ingredients (APIs) and may determine whether a drug candidate is abandoned during development or succeeds as a pharmaceutical. When creating different APIs, Albumin has been shown to have advantages over other excipients and to be able to help with some formulation difficulties. Historically, Albumin has been incorporated into a variety of formulations. Human serum albumin that was chemically defined (recombinant) is now more commonly used than the original form derived from plasma. Recombinant products are advantageous because they don't contain animal-derived ingredients, have a reliable supply, are highly pure, don't contain host-derived proteases, are homogeneous, have a high free thiol content, don't contain known or unknowable human pathogens, are consistent from batch to batch, and have a well-established regulatory pathway.
Moreover, Albumin is helpful in the production and administration of stem cell and other cell therapies, as well as numerous regenerative pharmaceutical products. Cell therapies frequently need to be cryopreserved for shipping and storage. To safeguard these sensitive biologic treatments, uniform, reproducible media is necessary, and HSA is frequently a key component. 7 In order to improve consistency, quality, and reproducibility, it is frequently used right from the start of the manufacturing processes for cell therapies. Additionally, it has been demonstrated to enhance adeno-associated virus vector transduction (AAVs). Such increasing use of Albumin is anticipated to boost the market CAGR during the forecast period.
Albumin (as Excipient) Market Segment Insights
Albumin (as Excipient) Type Insights
The Market segments of Albumin (as Excipient), based on Type, includes human, bovine, and recombinant serum albumin. The human segment held the majority share in 2022 in the Albumin (as Excipient) Market data. In the life sciences sector, recombinant human serum albumin is utilized for various purposes, such as microbial culture media and a component of cells, growth booster in recombinant DNA, blocking agent in blotting, and hybridoma technology. This is anticipated to fuel the segment's growth in the years to come. Recombinant serum albumin is anticipated to grow at the fastest CAGR during the forecast period owing to the increasing use of these in R&D activities..
Figure 2: Albumin (as Excipient) Market, by Type, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Albumin (as Excipient) Application Insights
The Albumin (as Excipient) Market data, based on Application, includes drug formulation, drug delivery, vaccines, medical device coating, and diagnostics. The drug delivery segment dominated the Albumin (as Excipient) market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Albumin's biochemical and biophysical characteristics make it a perfect drug delivery platform. Recent improvements in albumin-based therapies and our understanding of albumin physiology strongly incline us to believe that albumin-based therapies are superior to other technologies in terms of half-life, stability, versatility, safety, and ease of manufacturee.
Albumin (as Excipient) Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America Albumin (as excipient) market accounted for USD 0.4 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. It is anticipated that a number of research organizations and biopharmaceutical companies will increase their investments in the life sciences, which will likely boost the global market in these regions during the forecast period. The market is expanding due to the increasing use of plasma fractionation facilities and growing R&D activities in this region to the rising demand for Albumin. For instance, according to clinicaltrials.gov, as of June 2020, there were approximately 107 ongoing clinical trials in the United States involving Albumin in various stages of development and for multiple indications.
Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ALBUMIN (AS EXCIPIENT) MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Albumin market accounts for the second-largest market share. It is anticipated that introducing new products, adopting crucial initiatives like partnerships and acquisitions, and rising investments will propel the market. The biopharmaceutical industry's growing drug discovery and development efforts are anticipated to fuel the albumin market. Moreover, the UK market of Albumin (as excipient) held the largest market share, and the Germany market of Albumin (as excipient) was the fastest-growing market in the region.
Asia Pacific Albumin (as Excipient) Market is expected to grow at the fastest CAGR from 2022 to 2030. Some of the factors contributing to the growth of the market in this region include growing government investment and research and development for creating technologically advanced products. Additionally, it is anticipated that increasing rates of blood-related diseases in people, such as blood infections, will fuel the demand for Albumin in the years to come. Further, the China market of Albumin (as excipient) held the largest market share, and the India market of Albumin (as excipient) was the fastest-growing market in the region.
Albumin (as Excipient) Key Market Players & Competitive Insights
Major market players are launching new products that can be used to meet the rising demand from various end-use industries. Companies are also adopting various initiatives to grow their market share with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaborations with other companies.
One of the strategies adopted by manufacturers in the global Albumin (as excipient) industry to benefit clients is expanding the manufacturing capacities and manufacturing products locally. In recent years, the Albumin (as Excipient) industry has also had some investments that will be used in studying the product and its applications. The Albumin market major players include Albumedix A/S, Albumin Therapeutics, LLC Baxalta Incorporated, Baxter International Inc., Biotest AG, CSL Behring LLC, China Biologic Products Inc., Grifols International, HiMedia Laboratories Pvt. Ltd.
Albumedix A/S is a company that is the technology and product leader in the world for recombinant human Albumin. company's albumin-based technologies offer new ways to optimize drug dosing and improve therapeutic performance by extending the half-life, payload capacity, and tissue-specific delivery of active pharmaceutical agents. In March 2021, Albumedix Ltd. announced that they had signed a distribution contract with FUJIFILM Wako Pure Chemical Corporation (FUJIFILM Wako), a supplier of reagents, for Hong Kong, China, and Japan. The partnership reinforces Albumedix's dedication to regional biopharmaceutical and advanced therapy developers. According to the terms of the contract, FUJIFILM Wako will serve as a commercialization partner and distributor for Albumedix's recombinant human albumin products (Recombumin), including joint marketing initiatives in China, Hong Kong, and Japan.
Grifols is a global healthcare company that, since 1909, develops, produces and provides essential plasma-derived medicines and transfusion medicine. Grifols inaugurated its new albumin purification and filling facility at its global manufacturing and supply hub in Dublin, Ireland, for the production, packaging, and global distribution of Grifols treatments.
Key Companies in the market of Albumin (as excipient) includes
- Albumedix A/S
- Albumin Therapeutics
- LLC Baxalta Incorporated
- Baxter International Inc.
- Biotest AG
- CSL Behring LLC
- China Biologic Products Inc.
- Grifols International
- HiMedia Laboratories Pvt. Ltd., among others
Albumin (as Excipient) Industry Developments
April 2022 Apotex Corp. releases its generic version of Abraxane, Paclitaxel protein-bound particles for injection (albumin-bound), which was made available in the US. Adenocarcinoma of the pancreas, non-small cell lung cancer, and metastatic breast cancer are all indicated for treatment with paclitaxel protein-bound particles for injectable suspension.
May 2020 Bio Products Laboratory (BPL) announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection. The US and are currently in stock. The US Food and Drug Administration has given the drugs ALBUMINEX 5% and ALBUMINEX 25% approval for the treatment of cardiopulmonary bypass, acute nephrosis, acute respiratory distress syndrome (ARDS), ascites, and hypoalbuminemia, including that resulting from burns.
Albumin (as Excipient) Market Segmentation
Albumin (as Excipient) Type Outlook (USD Billion, 2018-2030)
- Arabica
- Robusta
- Others
Albumin (as Excipient) End-User Outlook (USD Billion, 2018-2030)
- Whole
- Ground
Albumin (as Excipient) Application Outlook (USD Billion, 2018-2030)
- Store-Based
- Non-Store-Based
Albumin (as Excipient) Regional Outlook (USD Billion, 2018-2030)
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
-
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
